KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $3.4 billion.

  • Bristol Myers Squibb's Cost of Revenue rose 1616.5% to $3.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 billion, marking a year-over-year increase of 2311.57%. This contributed to the annual value of $14.0 billion for FY2024, which is 3062.75% up from last year.
  • As of Q3 2025, Bristol Myers Squibb's Cost of Revenue stood at $3.4 billion, which was up 1616.5% from $3.4 billion recorded in Q2 2025.
  • In the past 5 years, Bristol Myers Squibb's Cost of Revenue registered a high of $4.8 billion during Q4 2024, and its lowest value of $2.3 billion during Q3 2021.
  • Its 5-year average for Cost of Revenue is $2.9 billion, with a median of $2.7 billion in 2023.
  • In the last 5 years, Bristol Myers Squibb's Cost of Revenue tumbled by 2241.94% in 2021 and then surged by 7530.05% in 2024.
  • Bristol Myers Squibb's Cost of Revenue (Quarter) stood at $2.4 billion in 2021, then rose by 10.06% to $2.6 billion in 2022, then rose by 5.86% to $2.7 billion in 2023, then surged by 75.3% to $4.8 billion in 2024, then fell by 28.62% to $3.4 billion in 2025.
  • Its Cost of Revenue was $3.4 billion in Q3 2025, compared to $3.4 billion in Q2 2025 and $3.0 billion in Q1 2025.